为什么要打造属于我国自己的人工智能底座？如何突破靶向药依赖进口的困境？大数据和人工智能如何 治理城市、改善民生？10月16日，在中央戏剧学院昌平校区，"社会主义是干出来的 新时代是奋斗出来 的"首都产业一线科技人才走进高校系列宣讲举行，来自智能建造、生物制药以及新一代信息技术三个 领域的首都产业一线科技人才现场分享自己在科研领域的"破冰"经历，坚定同学们的理想信念。 科技人才分享创业中的攻坚克难 在郑宇看来，能让他坚守在科研一线的原因有三点：对城市计算的科技信念，坚韧的意志，社会责任和 家国情怀。从业近二十年，他强烈地感受到，个人的发展跟祖国息息相关、紧密相连，只有祖国强大才 能提供优质的工作环境、完善的基础设施、充沛的科研资源，从而培育出更多优秀的个体。他告诉同学 们，个体也应以祖国的强大和发展为事业目标，顺应时代发展，乘势而行。 和王绍兰一样，其他两位科技人才也在创业中遇到过瓶颈和困境。首药控股（北京）股份有限公司副总 经理孙颖慧带来《为生命续航：中国创新药的自主研发》的宣讲。她讲到，经过十几年的历程，研制出 的靶向药将过去"无药可治"的困境，变成了"长期可控"的希望。 "听完王绍兰老师的分享，我深受触动 ...

Core Viewpoint - The article discusses the significant reduction in the price of HPV vaccines in China, highlighting the transition from high costs to more accessible options, and the inclusion of HPV vaccines in the national immunization program, which marks a major step towards public health improvement [6][33]. Group 1: HPV Vaccine Market Dynamics - In 2022, China reported 156,000 new cervical cancer cases, with nearly 60,000 deaths, accounting for about 20% of global totals [6]. - The HPV vaccine, particularly the nine-valent version, has been in high demand despite its high price, which was around 6,300 yuan for a three-dose package in 2021 [9][11]. - The vaccination rate for girls aged 9-14 in China was only 4% in 2022, significantly lower than the global average of 61.6% [11]. Group 2: Price Reduction and Accessibility - The introduction of free HPV vaccinations in certain regions, such as the Ordos region, has led to a dramatic increase in vaccination rates, reaching over 85% for girls aged 13-18 by the end of 2020 [15][20]. - By 2022, the price for a three-dose HPV vaccine in Beijing community hospitals dropped to 1,062 yuan, averaging 354 yuan per dose, which is half the price compared to earlier years [21]. - The first domestically produced HPV vaccine, priced at 329 yuan per dose, was launched in late 2019, significantly undercutting the prices of imported vaccines [26]. Group 3: Policy and Public Health Impact - The Chinese National Health Commission announced the inclusion of the HPV vaccine in the national immunization program, prioritizing coverage for girls aged 9-14 [33]. - The drastic price reduction and increased availability of HPV vaccines are expected to address health inequalities, particularly in rural and western regions of China where cervical cancer rates are higher [25][32]. - The article emphasizes that the focus should be on widespread vaccination rather than the perfection of vaccine types, highlighting the importance of accessibility in public health initiatives [18].

Core Viewpoint - Recently, Regeneron Biotech announced the launch of its personalized mRNA tumor vaccine (code RH125) clinical research project, which aims to evaluate the safety, tolerability, and therapeutic effects of the vaccine alone or in combination with PD-1 inhibitors in patients with advanced solid tumors [1] Group 1: Clinical Research Details - The study is an investigator-initiated exploratory clinical trial (IIT) co-initiated by Academician Xu Binghe and Director Chang Jianhua, who defined the clinical research protocol [1] - The trial focuses on assessing the personalized mRNA vaccine based on tumor neoantigens, addressing the limited treatment options and poor prognosis faced by advanced solid tumor patients [1] Group 2: Technological Advancements - Regeneron Biotech possesses leading artificial intelligence neoantigen prediction algorithms, mRNA nucleic acid delivery systems, and immune enhancement technologies [1] - The launch of RH125 in the IIT study is expected to provide new treatment options for patients with advanced solid tumors, potentially improving their quality of life [1]

Summary of Conference Call on Oncology Pipeline Company and Industry Overview - The conference call primarily discusses **Moderna's** oncology pipeline, focusing on their **Individualized Neoantigen Therapy (INT)** and **mRNA-4359** programs, which target melanoma and other cancers. The discussion includes insights from experts in the field of oncology, particularly regarding melanoma treatment advancements. Key Points and Arguments Pipeline Development - Moderna's pipeline has significantly expanded over the past few years, now including various cancer therapies such as **Individualized Neoantigen Therapy (INT)**, **cancer antigen therapies (CATs)**, and **T-cell engagers** [1][2][3] - The INT program is currently evaluating efficacy across multiple cancer types, including melanoma, lung cancer, renal cell carcinoma, and bladder cancer [3][4] Individualized Neoantigen Therapy (INT) - The INT program is unique in its approach, utilizing patient-specific tumor data to create personalized therapies. This involves sequencing tumor DNA and identifying unique mutations to predict immunogenic responses [4][5] - Recent data from a randomized phase II trial (P201) showed a **49% reduction in the risk of recurrence or death** and a **62% reduction in distant metastasis or death** for patients receiving INT combined with pembrolizumab compared to pembrolizumab alone [6][7] - The safety profile of INT was favorable, with no increase in immune-related adverse events compared to standard treatments [6][7] mRNA-4359 Program - mRNA-4359 targets both **PD-L1** and **IDO**, aiming to enhance T-cell responses against tumors. The mechanism is designed to address immune evasion and activate T-cells against cancer cells [21][24] - Preliminary data from an ongoing phase I-II trial indicated an **overall response rate of 24%** in heavily pretreated patients with refractory melanoma, which is notable given the patient population's history of resistance to prior therapies [32][33] - The safety profile of mRNA-4359 showed manageable adverse events, primarily mild symptoms such as injection site pain and fatigue, with no significant increase in high-grade immune-related adverse events [30][31][76] Melanoma Treatment Landscape - The discussion highlighted the evolving landscape of melanoma treatments, including the introduction of immune checkpoint inhibitors and combination therapies. Despite advancements, a significant unmet need remains for patients who do not respond to existing therapies [9][10][12] - The efficacy of combination therapies, such as anti-PD-1 and anti-CTLA-4, has been shown to be superior to single-agent therapies, but many patients still experience disease progression [11][12][15] Future Directions - Moderna plans to expand its clinical trials for mRNA-4359 to include combinations with other therapies, such as ipilimumab and nivolumab, and to explore its efficacy in non-small cell lung cancer [38] - The company is also investigating the potential of T-cell engagers and cell therapy enhancing programs, aiming to improve treatment outcomes for various cancers [39][40][41] Additional Important Insights - The conference emphasized the importance of biomarkers in identifying patients who may benefit from specific therapies, particularly in the context of precision medicine [33][34] - Ongoing translational research aims to better understand the mechanisms of action and patient responses to therapies, which is crucial for future drug development [51][52][53] This summary encapsulates the key discussions and findings from the conference call, highlighting Moderna's innovative approaches in oncology and the promising data emerging from their clinical trials.

Core Viewpoint - Rani Therapeutics' stock surged over 265% following a partnership announcement with Chugai Pharmaceutical, reaching a new high of $1.76 per share [1] Group 1: Partnership Details - The collaboration with Chugai Pharmaceutical is valued at up to $1.085 billion, including an upfront payment of $10 million [1] - Rani Therapeutics is eligible for up to $75 million in technology transfer and development milestone payments, $100 million in sales milestone payments, and single-digit royalties [1] - Chugai has the option to expand the partnership to five additional drug targets [1] Group 2: Company Overview - Rani Therapeutics specializes in oral delivery technology for biopharmaceuticals, with its core platform, RaniPill, focusing on oral antibodies and rare disease drug development [1] - The partnership aims to apply Rani's technology to Chugai's rare disease antibody projects, validating the application value of Rani's technology [1]

Core Viewpoint - Rani Therapeutics experienced a significant stock surge of over 265%, reaching a new annual high of $1.76, following the announcement of a collaboration agreement with Chugai Pharmaceutical worth up to $1.085 billion [1] Company Summary - Rani Therapeutics has entered into a collaboration agreement with Chugai Pharmaceutical, which includes an upfront payment of $10 million and potential milestone payments totaling up to $750 million for technology transfer and development, $100 million for sales milestones, and single-digit royalties [1] - The collaboration focuses on Rani Therapeutics' oral delivery technology for biologics, specifically utilizing its RaniPill® platform for the development of oral antibodies and treatments for rare diseases [1] - The partnership will apply to Chugai Pharmaceutical's rare disease antibody projects, validating the application value of Rani Therapeutics' technology [1]

Core Insights - The 2025 Sustainable Global Leaders Conference will be held from October 16 to 18 in Shanghai, focusing on women's leadership on the international stage [1] Group 1: Women's Leadership - Kolinda Grabar-Kitarović emphasized that leadership is not about who has the loudest voice but about constructive opinions and bridging differences [2] - She highlighted the unique value of sports in accelerating sustainable innovation and fostering cooperation [2] - Zhao Yan pointed out that women possess courage, resilience, insight, and empathy, which are essential for promoting long-term sustainability [3] Group 2: Sports and Women Empowerment - Zhao Ruirui stated that sports teach individuals to face wins and losses correctly, providing a platform for women to showcase their abilities [3] - She expressed that women embody miracles and can achieve extraordinary outcomes when given opportunities [3] Group 3: AI and Leadership - The impact of AI on women's leadership was discussed, with the consensus that AI will enhance rather than diminish women's unique value [5] - The historical context was provided, indicating that as AI liberates both physical and mental labor, the emotional intelligence and empathy of women will become increasingly important [5] Group 4: Conference Overview - The conference is co-hosted by the World Green Design Organization and Sina Group, with a focus on global action, innovation, and sustainable growth [6]

Group 1 - The 2025 Sustainable Global Leaders Conference will be held from October 16 to 18 in Huangpu District, focusing on "Facing Challenges Together: Global Action, Innovation, and Sustainable Growth" [2] - The conference will gather industry leaders and scholars to discuss sustainable development from various perspectives [3] - Several research reports will be released, including the "2024 China Wine Industry ESG Development Index Report" and "ESG Disclosure Progress Report" [4] Group 2 - China Construction Bank and other partners are supporting the conference, highlighting the collaboration between financial institutions and sustainable development initiatives [4] - The conference features discussions on the role of AI in sustainable development, emphasizing the need for a balance between innovation and ethical considerations [8][19] - Industry leaders are exploring the integration of ESG factors into business strategies, with a focus on long-term value creation [22][24] Group 3 - The importance of female leadership in sustainable development is emphasized, with discussions on unique traits that women bring to leadership roles [11][15] - The conference addresses the need for innovative governance structures and financial products to support sustainable practices in various sectors [6][12] - The role of AI in transforming industries and enhancing sustainability efforts is a key topic, with insights from experts on its potential and challenges [20][27] Group 4 - The conference highlights the significance of international cooperation in achieving global sustainability goals amidst geopolitical challenges [9][10] - Financial institutions are increasingly focusing on sustainable finance, with trends indicating a shift towards clearer regulatory frameworks and targeted capital allocation [24][36] - The discussions also cover the integration of sustainability into corporate strategies, with examples from various industries demonstrating successful practices [41][43]

Group 1 - The 2025 Sustainable Global Leaders Conference will be held from October 16 to 18 in Shanghai, focusing on women's leadership on the international stage [2] - The conference aims to explore sustainable development and the unique contributions of women in driving communication, resolving conflicts, and promoting collaboration [5][4] - The event is co-hosted by the World Green Design Organization and Sina Group, with support from the Shanghai Huangpu District Government, emphasizing global action and sustainable growth [9] Group 2 - Kolinda Grabar-Kitarović highlighted that leadership is not about who has the loudest voice but about constructive opinions and bridging differences [3] - She emphasized the unique value of sports in accelerating sustainable innovation and fostering cooperation, sharing insights on transforming temporary venues into permanent modular facilities [3] - Zhaoyan from Huaxi Group stated that women possess courage, resilience, and empathy, which are essential for long-term sustainable practices [5] Group 3 - Zhao Ruirui, a former Chinese volleyball player, noted that sports provide a platform for women to showcase their abilities and learn self-reliance and confidence [6] - She expressed that AI will not diminish women's leadership but will enhance their unique value, as emotional understanding becomes increasingly important in the AI era [8] - Qin Shuo argued that the AI era will strengthen women's leadership, as their empathetic and human-centered approach will be crucial in balancing technological advancements [8]

Core Points - The company, Heptagon Pharmaceuticals-B, repurchased 400,000 shares on October 17 at a price range of HKD 12.740 to HKD 13.100, totaling HKD 5.1349 million [2] - The stock closed at HKD 12.790 on the same day, reflecting a decline of 4.84%, with a total trading volume of HKD 74.9912 million [2] - Year-to-date, the company has conducted 52 repurchase transactions, acquiring a total of 22.793 million shares for a cumulative amount of HKD 156 million [2] Repurchase Details - On October 17, 2025, the company repurchased 40,000 shares at a maximum price of HKD 13.100 and a minimum price of HKD 12.740, with a total expenditure of HKD 513.49 thousand [2] - The repurchase activity has shown a consistent trend, with multiple transactions occurring throughout the year, indicating a strategic approach to managing share value [3] - The highest recorded repurchase price this year was HKD 15.330 on October 9, while the lowest was HKD 2.270 on January 8 [3]